Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders
Lorenzo Leggio, Christian S. Hendershot, Mehdi Farokhnia, et al.
Nature Medicine (2023) Vol. 29, Iss. 12, pp. 2993-2995
Closed Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: what do we know and future vistas
Roger S. McIntyre
Expert Opinion on Drug Safety (2024) Vol. 23, Iss. 5, pp. 539-542
Open Access | Times Cited: 16
Mapping the effectiveness and risks of GLP-1 receptor agonists
Yan Xie, Taeyoung Choi, Ziyad Al‐Aly
Nature Medicine (2025)
Closed Access | Times Cited: 15
Management of alcohol use disorder: a gastroenterology and hepatology-focused perspective
Luis Antonio Díaz, Daniel König, Sabine Weber, et al.
˜The œLancet. Gastroenterology & hepatology (2025)
Closed Access | Times Cited: 3
Once-Weekly Semaglutide in Adults With Alcohol Use Disorder
Christian S. Hendershot, Michael P. Bremmer, Michael B. Paladino, et al.
JAMA Psychiatry (2025)
Closed Access | Times Cited: 2
Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys
Anders Fink‐Jensen, Gitta Wörtwein, Mette Kruse Klausen, et al.
Psychopharmacology (2024)
Open Access | Times Cited: 11
Highway to the danger zone? A cautionary account that GLP‐1 receptor agonists may be too effective for unmonitored weight loss
Jesse R. Richards, Sahib S. Khalsa
Obesity Reviews (2024) Vol. 25, Iss. 5
Open Access | Times Cited: 9
Type 2 diabetes mellitus/obesity drugs: A neurodegenerative disorders savior or a bridge too far?
Katherine O. Kopp, Elliot J. Glotfelty, Yazhou Li, et al.
Ageing Research Reviews (2024) Vol. 98, pp. 102343-102343
Closed Access | Times Cited: 8
MetALD: Does it require a different therapeutic option?
George Marek, Harmeet Malhi
Hepatology (2024) Vol. 80, Iss. 6, pp. 1424-1440
Closed Access | Times Cited: 8
Weight loss therapy and addiction: increased risk after bariatric surgery but reduced risk with GLP-1 receptor agonists
André Scheen
Diabetes & Metabolism (2025), pp. 101612-101612
Closed Access | Times Cited: 1
The emerging role of glucagon-like peptide 1 in binge eating
Katherine N. Balantekin, Martin J. Kretz, Elizabeth G. Mietlicki‐Baase
Journal of Endocrinology (2024) Vol. 262, Iss. 1
Open Access | Times Cited: 7
Novel medications for problematic alcohol use
Markus Heilig, Katie Witkiewitz, Lara A. Ray, et al.
Journal of Clinical Investigation (2024) Vol. 134, Iss. 11
Open Access | Times Cited: 6
IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target
Nicolaus Bruns, Elizabeth H. Tressler, Leandro F. Vendruscolo, et al.
Pharmacological Research (2024) Vol. 207, pp. 107312-107312
Open Access | Times Cited: 6
Social media as pharmacovigilance: The potential for patient reports to inform clinical research on glucagon-like peptide 1 (GLP-1) receptor agonists for substance use disorders
Michael P. Bremmer, Christian S. Hendershot
Journal of Studies on Alcohol and Drugs (2023)
Closed Access | Times Cited: 14
GLP-1 and its analogues: Does sex matter?
Stina Börchers, Karolina P. Skibicka
Endocrinology (2024)
Open Access | Times Cited: 4
Substance Use and Concurrent Disorders: Current Context and the Need for Treatment Integration
Christian S. Hendershot, Bernard Le Foll
The Canadian Journal of Psychiatry (2025)
Closed Access
Repeated cycles of binge‐like ethanol consumption and abstinence alter neuropeptide mRNA in prefrontal and insular cortex, amygdala, and lateral hypothalamus of male and female C57BL/6J mice
Anne M. Dankert, Thomas L. Kash, Todd E. Thiele
Alcohol Clinical and Experimental Research (2025)
Closed Access
Effects of GLP‐1 Receptor Agonists in Alcohol Use Disorder
Mette Kruse Klausen, Gitte M. Knudsen, Tina Vilsbøll, et al.
Basic & Clinical Pharmacology & Toxicology (2025) Vol. 136, Iss. 3
Open Access
Gut Microbiome-Liver-Brain axis in Alcohol Use Disorder. The role of gut dysbiosis and stress in alcohol-related cognitive impairment progression: possible therapeutic approaches.
Emilio Merlo Pich, Ioannis Tarnanas, Patrizia Brigidi, et al.
Neurobiology of Stress (2025) Vol. 35, pp. 100713-100713
Open Access
Enfin libéré(e) de la nourriture ?
Lauren J. Young
Cerveau & Psycho (2025) Vol. Nº 174, Iss. 3, pp. 72-79
Closed Access
Blood phosphatidylethanol measurements indicate GLP‐1 receptor stimulation causes delayed decreases in alcohol consumption
Mathias E. Jensen, Mette Kruse Klausen, M Bergmann, et al.
Alcohol Clinical and Experimental Research (2025)
Open Access
Alcohol use disorder and body mass index show genetic pleiotropy and shared neural associations
Samantha G. Malone, Christal N. Davis, Zachary Piserchia, et al.
Nature Human Behaviour (2025)
Open Access
Inflammation in MASLD Progression and Cancer
Yeon Soo Kim, Y. C. Park, Hyunsoo Rho, et al.
JHEP Reports (2025), pp. 101414-101414
Open Access
An inhibitory GLP-1 circuit in the lateral septum modulates reward processing and alcohol intake in rodents
Christian E. Edvardsson, Davide Cadeddu, Mia Ericson, et al.
EBioMedicine (2025) Vol. 115, pp. 105684-105684
Closed Access
Integrated and collaborative care across the spectrum of alcohol-associated liver disease and alcohol use disorder
Lamia Haque, Lorenzo Leggio
Hepatology (2024) Vol. 80, Iss. 6, pp. 1408-1423
Closed Access | Times Cited: 3
Contribution of Visceral Systems to the Development of Substance Use Disorders: Translational Aspects of Interaction between Central and Peripheral Mechanisms
Д. И. Перегуд, N. V. Gulyaeva
Biochemistry (Moscow) (2024) Vol. 89, Iss. 11, pp. 1868-1888
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top